Therapy Areas: Oncology
Merck reports positive Phase 3 results for KEYTRUDA in advanced endometrial cancer
15 July 2026 - US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, announced on Wednesday that its Phase 3 KEYNOTE-C93 trial evaluating KEYTRUDA (pembroliz...
Kelun-Biotech's Phase III study of sac-TMT in combination with pembrolizumab meets primary endpoint
15 July 2026 - Chinese pharmaceutical company Sichuan Kelun-Biotech Biopharmaceutical Co Ltd (HK:6990) announced on Tuesday that a Phase III clinical study (OptiTROP-Lung06) of its trophoblast cell-su...
AstraZeneca signs global licence deal with Dizal for lung cancer drug Zegfrovy
14 July 2026 - Biopharmaceutical company AstraZeneca PLC (STO: AZN; LON: AZN; NYSE: AZN) announced on Tuesday that it has agreed an exclusive worldwide licence with China's Dizal Pharmaceutical C...
Summit Therapeutics sells Phase III antibiotic asset ridinilazole to Biossil
14 July 2026 - Biopharmaceutical oncology company Summit Therapeutics Inc (NASDAQ:SMMT) on Tuesday announced an agreement to sell ridinilazole, an investigational Phase III precision antibiotic, to To...
European Commission approves Erbitux combination for first-line BRAF V600E-mutant mCRC
14 July 2026 - US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, announced on Tuesday that the European Commission has approved an updated label for Erbi...
Newbury Pharmaceuticals receives Swedish approval for generic tofacitinib
13 July 2026 - Swedish pharmaceutical company Newbury Pharmaceuticals AB (STO:NEWBRY) announced on Monday that it has received marketing authorisation in Sweden for Tofacitinib Newbury 5 mg and 10 mg ...